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Poliomyelitis, caused by poliovirus, is on the verge of eradication, and the world is preparing to shift from
live to inactivated polio vaccine. In view of the requirement of non-infectious reagents, especially protein
antigens, for surveillance during the ﬁnal phase of poliovirus eradication, we have attempted to generate
reagents that may be of use for the development of diagnostic tests. Polioviral proteins VP0, VP3, VP1,
and 3AB were expressed in Escherichia coli using the autoinduction system, puriﬁed, and the proteins
were used to raise antisera in rabbits. All antisera detected all three serotypes of PV from infected cell
lysates in enzyme-linked immunosorbent assay, immunoﬂuorescence and western blotting.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Polio is an acute viral infectious disease of humans, and is
caused by poliovirus (PV). PV is a single-stranded positive sense
RNA virus belonging to the genus Enterovirus of the family Picor-
naviridae. PV is classiﬁed into three serologically distinct types, PV1,
PV2, and PV3, each with slight differences in capsid structure,
which are differentially recognized in virus neutralization assays.
The PV genome is about 7500 nucleotides long, and consists of a
single open reading frame ﬂanked by a 50 non-translated region
(NTR), which includes the internal ribosome entry site (IRES),
30NTR, and a polyA tail. The small viral protein VPg is covalently
linked to the 50 end of the genome. Translation of the viral genome
results in the synthesis of a polyprotein, which is cleaved by viral
proteases into individual viral proteins, including (a) three struc-
tural proteins VP1, VP3 and VP0, the latter of which is further
processed into VP4 and VP2 during virion morphogenesis, and (b)
seven non-structural proteins (NSP's: 2A, 2B, 2C, 3A, 3B, protease
3C, and RNA-dependent RNA polymerase 3D). The 2A and 3C pro-
teins are responsible for the proteolytic cleavage of the polyprotein
[1,2].
Three major antigenic sites with neutralization epitopes are
present on the surface of PV and the location of the antigenic sitesegde).
r Inc. This is an open access articlediffers among serotypes. Antigenic site 1 (residues 89e100 of VP1)
is present in PV2 and 3, antigenic site 2a (residues 220e222 of VP1)
is present in PV1, antigenic site 2b (residues 164e172 of VP2) is
present in PV1 and 3, antigenic site 3a (residues 286e290 of VP1) is
present on PV3, whereas antigenic site 3b (residues 58e60, 70, 71,
77, 79 of VP3) is present in PV1 and 3 [3,4]. Cross-reactive anti-
bodies that bind to PV receptor binding site and neutralize PV1 and
2 have also been reported [5]. Apart from neutralizing antibodies,
non-neutralizing cross-reactive antibodies raised against dena-
tured antigen can recognize all three serotypes of PV [6,7]. In
addition to antibodies to structural proteins, infected hosts also
produce antibodies against non-structural proteins [8,9]; however,
antibodies against NSP's of PV are more likely to be serotype-
independent, compared to antibodies to structural proteins.
Seromonitoring of mass vaccination campaigns requires
demonstration of high antibody titers against structural proteins,
especially VP1. On the other hand, demonstration of anti-NSP an-
tibodies in the sera is an indication of infection. The 3AB protein is
absent in puriﬁed inactivated vaccines, and antibodies against NSP
indicate circulation of PV in a population. Immunological assays
developed based on recombinant PV proteins could therefore be
useful for demonstration of freedom from infection status after
cessation of oral polio vaccine.
The inducible T7 expression system is widely used for
expressing foreign genes in E. coli [10,11]. In general, the cells are
grown to increase the mass before inducing protein expression.
Alternatively, an autoinduction system [12,13] can be employed,under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Primers used for ampliﬁcation of PV genes.
Primer name Sequence (50e30; enzyme sites in bold face)
PV1-VP0EcoRI F ATACGAATTCATGGGTGCTCAGGTTTCATCACAGA
PV1- VP0HindIII R TAACAAGCTTTTATCACTGTAAGCGTGGCAGGGTAATGT
PV1-VP3EcoRIF ATACGAATTCGGCCTGCCGGTCATGAACAC
PV1-VP3HindIII R TAACAAGCTTTTATCACTGTGCTAGCGCTTTTTGCTCT
PV1- VP1EcoRIF GGATGAATTCGGGTTAGGTCAGATGCTTGAAA
PV1- VP1HindIIIR TGGCAAGCTTTTATCAATATGTGGTCAGATCCTTGGTGGA
PV1- 3ABEcoRI F TATCGAATTCGGACCACTCCAGTATAAAGAC
PV1- 3ABHindIII R GCTCAAGCTTTTATCATTGTACCTTTGCTGTCCTAATG
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used up, and the cell switches to lactose as the sole source of car-
bon. This method is advantageous because there is no need to
monitor either the cell growth or the time of induction during
autoinduction. In the current study, the autoinduction system was
used to express VP0, VP3, VP1 and 3AB genes of PV1 in E. coli, and
antisera raised using the recombinant proteins was tested for their
suitability to detect different serotypes of PV in different
immunoassays.
2. Materials and methods
2.1. Plasmids and Escherichia coli (E. coli) strains
The pRSET B (Invitrogen, Bengaluru, India) plasmid was used for
cloning and expression of genes of interest under the control of the
T7 f10 promoter. The E. coli DH5a strain (Invitrogen) was used for
cloning of genes, while E. coli BL21(DE3) strain (Invitrogen) was
used for protein expression.
The pVS(1)IC-O(T) plasmid (kind gift from Dr. Akio Nomoto,
Tokyo University, Japan), which contains the full length PV1
genome under the control of SV40 promoter [14], was used as an
infectious plasmid to produce PV1.
2.2. Viruses and cells
CV1 (ATCC-CCL-70) is a ﬁbroblast cell line derived from male
African green monkey kidney. CV1 cells are susceptible for polio-
virus infection [15].
Sabin strains of PV1, PV2, and PV3 were obtained from Bharat
Biotech International Limited, Hyderabad, India. Recombinant PV1
(rPV1) was generated using plasmid pVS(1)IC-O(T) by transfecting
CV1 cells (ATCC-CCL-70). For making lysates, all virus infections
were carried out at 0.1 multiplicity of infection (MOI), whereas for
immunoﬂuorescence, MOI of 0.01 (PV1) or 0.05 (PV2 and PV3)were
used. All experiments were carried out in biosafety level II labo-
ratory, following appropriate protocols and procedures.
2.3. Bacterial culture media
The following bacterial culture media were used in the present
study:
LB-SP medium: 1% soy peptone, 0.5% yeast extract, 1% sodium
chloride.
ZYP-0.8G-SP medium: 1% soy peptone, 0.5% yeast extract,
50 mM Na2HPO4, 50 mM KH2PO4, 25 mM (NH4)2SO4, 2 mMMgSO4
and 0.8% glucose.
ZYP-5052-SP medium for autoinduction: 1% soy peptone, 0.5%
yeast extract, 50 mM Na2HPO4, 50 mM KH2PO4, 25 mM (NH4)2SO4,
2 mM MgSO4, 0.5% glycerol, 0.05% glucose and 0.2% a-lactose.
2.4. Cloning of polioviral genes
VP0, VP3, VP1 and 3AB genes of Sabin PV1 (AY184219.1) were
ampliﬁed by RT-PCR using gene-speciﬁc primers with ﬂanking re-
striction sites EcoRI and HindIII (Table 1) and cloned into pRSET B in
frame with the N-terminal His-tag, using standard procedures [16].
2.5. Transformation and expression of genes
The recombinant plasmids pPV1VP0, pPV1VP3, pPV1VP1,
pPV13AB as well as control pRSET B (not containing any insert)
were transformed into chemically competent BL21(DE3) cells [17].
Transformed cells were grown in onemL of LB-SP broth. After 1 h of
incubation at 37 C, 100 mL of the culture was spread on LB-SP agarcontaining 2% glucose with 100 mg/mL of ampicillin for selection,
and incubated at 37 C overnight. From each transformed plate a
few colonies were transferred to 2 mL of ZYP-0.8G medium con-
taining ampicillin (100 mg/mL) and incubated in a rotary shaker at
200 rpm at 37 C. After 6e8 h, 100 mL of the culture was inoculated
into 200 mL of ZYP-5052 autoinduction medium with antibiotic,
and further grown in culture with shaking at 37 C overnight. The
resulting culture was centrifuged (1500g for 10 min), and the cells
were used for analysis.
2.6. SDS-PAGE and western blotting
OnemL of autoinduced culture was pelleted and resuspended in
1X reducing SDS-PAGE loading buffer, boiled at 95 C for 10 min,
subjected to 12% denaturing SDS-PAGE and stained with Coomassie
brilliant blue R-250. Gels were blotted to PVDF membranes for
western blot analysis. The membrane was blocked with 5% w/v
skimmed milk powder (SMP) in phosphate buffered saline, pH 7.2
(PBS), overnight at 4 C. The membrane was incubated with anti-
His monoclonal antibodies (Sigma-Aldrich, Bengaluru, India) at a
dilution of 1:15,000 in 3% SMP in PBS at 37 C for 1 h, washed three
times with PBS containing 0.05% Tween-20 (PBST), followed by
incubation with a 1:10,000 dilution of horseradish peroxidase
(HRP) conjugated anti-mouse IgG secondary antibody in 3% SMP at
37 C for 1 h. The membranes were washed three times with PBST,
and once with PBS, then incubated with ECL reagent (Thermo Sci-
entiﬁc, Bengaluru, India), and His-tagged proteins were detected
using X-ray ﬁlm.
2.7. Protein solubility
Ten mL of autoinduced cultures were pelleted and resuspended
in 10 mL of 50 mM Tris (pH 8.0) buffer containing 25% sucrose, 0.5%
Triton X-100, and 1 mM phenyl methyl sulfonyl ﬂuoride (PMSF).
Cells were lysed by sonication (10 cycles of 15 s pulse with intervals
of 30 s each, at 60% amplitude) on ice, and the lysate was pelleted
by centrifugation at 16,000g for 10 min. The supernatant and pellet
were collected separately and analyzed on reducing SDS-PAGE.
2.8. His-tag based nickel-nitriloacetic acid (Ni-NTA) protein
puriﬁcation
2.8.1. Puriﬁcation of soluble proteins
Sonicated lysate was clariﬁed by centrifugation at 16,000g for
5 min, and used to load a Ni-NTA column pre-equilibrated with
50 mM Tris-HCl, 0.3 M NaCl, 20 mM imidazole, pH 8.0 (soluble
protein equilibration buffer). The columnwas washed with 50 mM
TriseHCl, 0.3 M NaCl, 20 mM imidazole, pH 8.0 (soluble protein
wash buffer), until the OD at A280 reached zero, and the column-
bound protein was eluted with 50 mM TriseHCl, 0.3 M NaCl,
250 mM imidazole, pH 8.0 (soluble protein elution buffer). The
elution fractions were analyzed on reducing SDS-PAGE, and
Fig. 1. Expression and puriﬁcation of PV proteins in E. coli: Induced proteins were subjected to reducing SDS-PAGE and visualized by Coomassie blue staining. Speciﬁc protein
expression from each gene can be observed by comparison with pRSET B E. coli lysate. (A) PV1-VP0, (B) PV1-VP3, (C) PV1-VP1, (D) PV1-3AB gene expression, solubility and pu-
riﬁcation using Ni-NTA chromatography. Vec: pRSET B vector control, L: total cell lysate after induction, S: supernatant after sonication, P: pellet after sonication, E: different elution
fractions after puriﬁcation, M: molecular weight marker standards (Sigma-Aldrich) containing bovine serum albumin e A7517 (~66 kDa), chicken ovalbumin e A7642 (~45 kDa),
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) e G5262 (~35 kDa), bovine pancreatic trypsinogen e T9011 (~24 kDa), and bovine a-lactalbumin e L6385 (~14 kDa).
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dialyzed against 100 mM Tris, pH 8.0 overnight at 4 C. Protein
concentration was estimated by BCA protein assay kit (Thermo
Scientiﬁc) according to the manufacturer's instructions.
2.8.2. Puriﬁcation of proteins from inclusion bodies
After sonication, the cell pellet was dissolved in 10 mL of
50mMTris-HCl, 8 M urea, pH 8.0 (denatured protein equilibration
buffer), clariﬁed by centrifugation at 16,000g for 5 min, and the
supernatant was loaded onto a Ni-NTA column pre-equilibrated
with denatured protein equilibration buffer. The column was
washed with 50 mM Tris-HCl, 8 M urea, 20 mM imidazole, pH 8.0
(denatured protein wash buffer) until OD at A280 reached zero, and
column bound proteins were eluted with 50 mMTriseHCl, 8 M
urea, 250 mM imidazole, pH 8.0 (denatured protein elution buffer)
and collected fractions were analyzed by reducing SDS-PAGE.
Fractions with presumed desired protein were pooled, and urea
was removed by step dialysis through a graded series of urea (6 M,
4 M, and 2 M) in 100 mM Tris, pH 8.0, for 2 h each, followed by a
ﬁnal dialysis against 100 mM Tris, pH 8.0, overnight, all at 4 C.
Protein concentration was estimated by BCA protein assay kit
(Thermo Scientiﬁc) according to the manufacturer's instructions.
2.9. Production of hyperimmune sera
Animal experiments were conducted with permission from the
Institutional Animal Ethics Committee as per the Guidelines of the
Committee for the Purpose of Control and Supervision of Experi-
ments in Animals, under the Breeding of and Experiments on An-
imals (Control and Supervision) Rules, 1998 as amended in 2001
and 2006, Government of India.
Five hundred micrograms of the puriﬁed recombinant proteins
(PV1-VP0, -VP3, -VP1 and -3AB) each were mixed individually with
equal volume of Freund's incomplete adjuvant (FIA) to make anFig. 2. Conﬁrmation of tagged proteins: Five mL of each of the column puriﬁed
proteins were subjected to reducing SDS-PAGE, blotted, and the His-tagged proteins
were detected using anti-His antibodies. Vec: pRSET B vector control, M: molecular
weight marker (Color Prestained Protein Standard, NEB, Cat. no-P7712L).emulsion and injected into 2-month-old New Zealand white rab-
bits subcutaneously. On day 28, the animals were boosted with
250 mg of respective protein emulsions in FIA. On day 35, sera were
tested for the ability to detect PV-speciﬁc proteins by western
blotting. A second booster of 250 mg of respective protein emulsions
in FIA was administered on day 56, and sera obtained at day 66
were stored at 20 C.2.10. Immunological reactivity of antibodies
The sera were tested for their ability to detect three serotypes of
PV as well as rPV1. CV1 cells were infected with PV1, PV2, or PV3
viruses, or transfected with pVS(1)IC-O(T) plasmid. At 30% cyto-
pathic effect, cell lysates were prepared by freeze-thawing in PBS,
and used for western blotting and ELISA. Similarly, the ability of the
antisera to detect the three serotypes of PV by immunoﬂuorescence
assay was tested on CV1 cells infected with PV1, PV2, or PV3
viruses.Fig. 3. Detection of PV proteins in infected cells by polyclonal sera: CV1 cells were
separately infected with the three serotypes of PV, or left uninfected. The cells were
harvested 48 h post-infection and lysates were subjected to reducing SDS-PAGE and
western blotting using rabbit polyclonal antibodies (anti-PV1-VP0 sera for panel-A,
anti-PV1-VP3 sera for panel-B, anti-PV1-VP1sera for panel-C and anti-PV1-3AB sera
for panel-D). rPV1 lysate was prepared by transfecting CV1 cells with pVS(1)IC-O(T)
plasmid. M: molecular weight marker (Color Prestained Protein Standard, NEB,
Cat.no-P7712L).
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ELISA plates were coated with PV1, PV2, or PV3 infected or
uninfected CV1cell lysates (100 mg of total protein/well) or re-
combinant proteins (100 ng/well) overnight at 4 C. The plateswere
blocked with 3% SMP in PBS for 1 h at 37 C. Different polyclonal
sera at various dilutions (1:200 to 1:3200) in 1% SMP in PBS were
added and incubated at 37 C for 1 h, washed three times with PBST,
followed by addition of HRP-conjugated anti-rabbit IgG (Sigma-
Aldrich) at 1:5000 dilution in 1% SMP at 37 C for 1 h. The plate was
washed three times with PBST and once with PBS, and then
developed using o-phenylene diamine (OPD) substrate. The reac-
tionwas stopped by addition of 50 mL of 3 M sulphuric acid per well
and the OD was read at 490 nm. The ELISA data was analyzed using
one-way analysis of variance (GraphPad Prism). The p values were
calculated by comparing lysates from control CV1 cells to lysates
from CV1 cells infected with PV1, PV2 or PV3, using Bonferroni's
multiple comparison test.
2.10.2. Western blotting
Lysates of PV1-, PV2-, or PV3-infected CV1 cells, or extracts of
pVS(1)IC-O(T) plasmid- or mock transfected CV1 cells were sub-
jected to reducing SDS-PAGE and transferred to a PVDF membrane.
Anti-PV1-VP0, -VP3, -VP1or -3AB rabbit sera were used as primary
antibody (1:1000) and HRP-conjugated anti-rabbit IgG (Sigma-
Aldrich) (1:5000) was used as secondary antibody to develop
western blot using ECL reagent (Thermo Scientiﬁc) to detect
respective PV proteins.
2.10.3. Immunoﬂuorescence
CV1 cells were infected with PV1 (0.01MOI), PV2 (0.05 MOI), or
PV3 (0.05MOI), and incubated at 37 C for 18 h. The cells were ﬁxed
with methanol: acetone (1:1) mixture at room temperature for 3
min, and washed twice with PBS. Rabbit anti-VP0, -VP3, -VP1 or
-3AB polyclonal sera were added to each well at 1:200 dilution, and
incubated at 37 C for 1 h, and the plates were washed three times
with PBS. Then, ﬂuorescein isothiocyanate (FITC)-conjugated anti-
rabbit IgG (Sigma-Aldrich) (1:500 dilution) was added, before in-
cubation at 37 C for 1 h, and two washes with PBS. The cells were
then observed under a ﬂuorescent microscope.Fig. 4. Testing of polyclonal sera in ELISA: The ELISA plates were coated with CV1 cell lysa
(against VP0, VP3, VP1, and 3AB) along with their pre-immune sera (denoted ‘P’) were used a
error bar shows the standard deviation of duplicate samples. Cut-off to declare positivity (h
were calculated by comparing control CV1 lysate with PV1, PV2 or PV3 lysates using Bonfe3. Results and discussion
3.1. Cloning PV genes, and expression and puriﬁcation of PV
proteins
The ampliﬁed PCR products for PV1 VP0, VP3, VP1 and 3AB genes
were cloned into pRSET B plasmid, and positive clones (pPV1VP0,
pPV1VP3, pPV1VP1, pPV13AB) were conﬁrmed by restriction
digestion and nucleotide sequencing. All the genes were expressed
individually in E. coli BL21(DE3) using autoinduction [13]. Expres-
sion of the proteins in the induced cultures was assessed by visu-
alization of an additional protein band in the induced cultures
compared to controls on reducing SDS-PAGE (Fig. 1; panel A for
VP0, panel B for VP3, panel C for VP1 and panel D for 3AB). Addi-
tional bands corresponding to VP0 (42 kDa), VP3 (31 kDa), VP1
(38 kDa) and 3AB (17 kDa) were also observed compared to the
controls. The molecular weights of all the recombinant proteins
were approximately 5 kDa greater than the native viral proteins
due to fusion of N-terminal coding sequences from the vector (His
tag, T7 gene10 leader, Xpress epitope tag and enterokinase recog-
nition site). Proteins VP0, VP3 and VP1 were present in the insol-
uble fraction (inclusion bodies; pellet fraction with each of the
proteins in Fig. 1). This was not surprising since PV structure is
formed by 60 copies each of VP0, VP1 and VP3, and these proteins
may not fold properly when expressed independently, leading to
inclusion body formation [18]. These proteins were denatured with
urea before applying for puriﬁcation on Ni-NTA column. In the case
of 3AB, the protein was present in both soluble and insoluble
fractions (Fig 1, panel D, middle). The presence of 3AB in the
insoluble fraction is not unexpected as the protein has been shown
to be membrane-associated in both virus-infected eukaryotic cells
[19] and when expressed in E. coli [20]. However, for the ease of
puriﬁcation, only soluble fraction of 3AB was used. Puriﬁcation on
Ni-NTA column resulted in more than 90% purity for all the
expressed proteins. The ﬁnal puriﬁed protein yields obtained when
cultured in shake ﬂasks were 36 mg (VP0), 16 mg (VP3), 28 mg (VP1),
and 19 mg (3AB) per mL of culture, respectively. When dialyzed
samples of pooled elution fractions were subjected to western
blotting, anti-His antibodies could detect speciﬁc bands of all thetes infected with PV1, PV2, or PV3, or uninfected cell lysates. Different polyclonal sera
s primary antibody followed by HRP-conjugated secondary antibody for detection. The
orizontal line) was taken as three times the average of pre-immune sera. The p values
rroni's multiple comparison test.(*P value < 0.001).
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band of the proteinwas observed (Fig. 2). This latter band could be a
degradation product of VP3 protein where the C-terminus was lost,
since the recombinant protein was generated using an N-terminal
His-tag. The slight discrepancy in the apparent molecular weight of
3AB between Figs. 2 and 3 could be due to differential migration of
unstained versus pre-stained molecular size markers, respectively.
3.2. Reactivity of hyperimmune sera
The anti-PV1-VP0 sera could detect both VP0 (37 kDa) and VP2
(30 kDa) proteins in western blot analysis of lysates from cells
infectedwith all three serotypes of PV, or transfected to obtain rPV1Fig. 5. Testing of polyclonal sera in immunoﬂuorescence: Cell monolayers were infecte
(against VP0, VP3, VP1 and 3AB) were used as primary antibody followed by FITC-conjuga(Fig. 3, panel-A). However, only a faint band of VP2 was observed
with PV2 lysate. Similarly, the anti-PV1-3AB sera could detect 3AB
(12 kDa) in all the samples, except lysates from cells alone (Fig. 3,
panel-D). In case of homologous virus (PV1 and rPV1) the sera
could detect 3A protein also. These results indicate that both the
sera could detect uncleaved and cleaved proteins in case of proteins
of homologous virus, whereas detection of cleaved protein varied in
case of proteins of heterologous viruses. The anti-PV1-VP3 sera
could detect VP3 (26 kDa) from all the serotypes of PV as well rPV1
(Fig. 3, panel-B). In the case of anti-PV1-VP1 sera, VP1 (33 kDa) of all
serotypes of PV could be detected; however, the signal was better
with PV1 (both PV1 and rPV1) as compared to that with PV2 and
PV3 (Fig. 3, panel-C). It is worth noting that VP1 is a serotype-d with PV1, PV2, or PV3, or left uninfected. Different polyclonal sera raised in rabbits
ted secondary antibody for detection.
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different serotypes can be observed [7,21]. This could be the reason
for the observation of better signal with homotypic than the het-
erotypic VP1. Further, a difference was observed in themobility (gel
shifting) of VP0 and VP1 proteins of different serotypes of PV (Fig. 3,
panels A and C). Similar differences in mobility of PV proteins have
been reported earlier [22,23]. The formula weight of the VP0 and
VP1 proteins of all the serotypes is similar; however, they differ in
charge, which may be contributing to the shifting of these proteins
on SDS-PAGE. Gel shifting is a common phenomenon observed in
highly acidic or basic proteins, as well as proteins with proline
kinks, and among mutant proteins with one or two amino acid
changes [24e27]. By ELISA, hyperimmune sera could detect E. coli
expressed recombinant proteins (Supplementary Information S.
Fig. 1) as well as viral protein in the PV-infected cell lysates
(Fig. 4, Supplementary Information S. Fig. 2). ELISA results were
similar to western blot analysis, in that (a) all antisera could detect
PV1, PV2, and PV3, (b) anti-VP1 antibodies reacted better with
homologous virus (PV1) than with heterologous viruses (PV2 or
PV3), and (c) anti-VP0 sera showed some background reactivity
with CV1 cell lysate (Fig. 4; also compare with data in Fig. 3). Sig-
niﬁcant difference was observed with all polyclonal sera when OD
values were compared between control (uninfected) CV1 cells and
CV1 cells infected with PV1, PV2 or PV3 (P > 0.001).
As expected, all sera also showed signal in cells infected with all
three serotypes of PV, and no signal was observed in uninfected
cells by immunoﬂuorescence assay (Fig. 5). Pre-immune sera did
not show any background staining with cells infected with PV (data
not shown). However, in contrast to the results with western blot
and ELISA, no observable difference in ﬂuorescence intensity
among the serotypes could be detected. This could possibly be due
to the lower sensitivity of the assay as well as potential higher
background in infected cells.
Detection of PV proteins in western blot, ELISA and immuno-
ﬂuorescence indicate that the sera could detect both native and
denatured proteins. Antibodies developed during this study can be
used for vaccine identity test and probably also for potency testing,
and we are currently exploring these applications with a vaccine
manufacturer. It should be noted that extensive standardization in
terms of production, puriﬁcation, and quality control of the pro-
teins is required to use them as validated reagents. Similarly, the
polyclonal sera also need to be extensively characterized. In this
context, characterized monoclonal antibodies may provide more
standardized antibody reagents, although polyclonal antibodies
cover multiple reactive sites on a protein.
4. Conclusions
Owing to the PV eradication initiative, the incidence of polio due
to wild type virus is on the verge of approaching zero. In this
transitory period, the oral, live attenuated vaccine is being replaced
by the injectable, inactivated vaccine [28,29]. As we move towards
containment of live polioviruses followed by destruction of the
stocks, protein- and not virus-based reagents are essential both for
evaluation of immune responses as well as for surveillance studies
to detect circulating vaccine-derived PV's. The reagents generated
(both proteins and antisera) in this study are a step forward in the
development of analytical assays useful for virus identity during
vaccine manufacturing and also for development of immunoassays
for monitoring the eradication program.
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